An experimental malaria vaccine once thought promising is turning out to be a disappointment, with a new study showing it is only about 30 percent effective at protecting infants from the killer disease.
Glaxo first developed the vaccine in 1987 and has invested $300 million in it so far.
WHO said it couldn't comment on the incomplete results and would wait until the trial was finished before drawing any conclusions.
___
Online:
www.nejm.org
Copyright 2012 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.
Reader Comments (